Compare MasTec Inc (MTZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs TG Therapeutics Inc — how do they compare? MasTec Inc trades at $212.65 (market cap $17.40B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: MasTec Inc is far larger — about 2.1× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and TG Therapeutics Inc for 16 Days on average.
| MTZ | TGTX | |
|---|---|---|
Market Cap | $17.40B | $8.16B |
Volume | 1,415,821 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $437.51 | $59.06 |
52-Week Low | $190.08 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $20.32B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $216.66, down 3.0% on the day, with technical indicators showing bearish momentum as the stock trades below key moving averages. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 89% buy ratings and a consensus price target of $408.58, representing significant upside potential from current levels.
MTZ presents a compelling growth story with record $21.4B backlog and exposure to infrastructure investment cycles, though premium valuation metrics and recent cash flow weakness warrant caution. The stock's current discount to analyst targets offers opportunity, but execution risks in communications segment and competitive pressures require monitoring.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
